Meeting
2021 ASCO Annual Meeting
Long-term follow-up results of a multicenter first-in-human study of the dual BCMA/CD19 Targeted FasT CAR-T GC012F for patients with relapsed/refractory multiple myeloma.
Authors
Hua Jiang
Shanghai Chang Zheng Hospital, Shanghai, China
Hua Jiang , Baoxia Dong , Li Gao , Li Liu , Jian Ge , Aili He , Lu Li , Jing Lu , Xiequn Chen , Martina A. Sersch , Lianjun Shen , Xun Ye , Hua Zhang , Yi Zhao , Jia Liu , Weijun Fu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT04236011; NCT04182581
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8014)
DOI
10.1200/JCO.2021.39.15_suppl.8014
Abstract #
8014
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Association of frailty and high-risk immuno-nutritional score with outcomes in patients with relapsed and refractory multiple myeloma treated with chimeric antigen receptor T-cells.
First Author: Karnav Modi
Poster
2023 ASCO Annual Meeting
Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies.
First Author: Ross Firestone
Poster
2022 ASCO Annual Meeting
Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Real-world experience.
First Author: Doris K. Hansen
Poster
2022 ASCO Annual Meeting
Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI.
First Author: Saad Zafar Usmani